Company Dossier · Health Care
Krystal Biotech
- MidCap 400
What Krystal Biotech is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 23, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $0.44 billion, up 22% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.26 billion, up 37% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.01 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Latest earnings call or results release (August 3, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 17, 2026): 0 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $26.2 million on the open market.SEC Form 4
- 423 institutional managers reported a position at June 30, 2026 (+55 on the quarter before).SEC Form 13F
- H-1B filings certified in Q1 2026: 2.U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Krystal Biotech yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
What the company says
Hiring and ownership
In the news
Headlines that name Krystal Biotech, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NegativeKrystal Biotech Stock: VYJUVEK’s Success Is Becoming Its Growth Problem (Downgrade)
seekingalpha.com · via Marketaux · Oct 10, 2026
- NeutralKrystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value (NASDAQ:KRYS)
seekingalpha.com · via Marketaux · Oct 10, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Jun 16, 2026Patent
- May 20, 20268-KShareholder vote resultsItem 5.07
- Mar 24, 2026Patent
- Feb 17, 202610-KAnnual report (10-K)0 risk factors added, 1 removed
- Jan 13, 2026Patent
- Dec 23, 20258-KDirector or officer changeItem 5.02
- Jul 22, 2025Patent
- May 19, 20258-KShareholder vote resultsItem 5.07
- Feb 19, 202510-KAnnual report (10-K)3 risk factors added, 1 removed
- Oct 29, 2024Patent
- Feb 26, 202410-KAnnual report (10-K)18 risk factors added, 4 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Doximity DOCS | $0.7B | — | Jun 30, 2026 |
| Arrowhead Pharmaceuticals ARWR | $0.7B | −$0.1B | Jun 30, 2026 |
| BridgeBio Pharma BBIO | $0.7B | −$0.4B | Jun 30, 2026 |
| Axsome Therapeutics AXSM | $0.8B | −$0.1B | Jun 30, 2026 |
| Repligen RGEN | $0.8B | $0.1B | Jun 30, 2026 |
| Corcept Therapeutics CORT | $0.8B | $0.1B | Jun 30, 2026 |
| Ionis Pharmaceuticals IONS | $0.9B | −$0.6B | Jun 30, 2026 |
| Caris Life Sciences CAI | $1.0B | $0.1B | Jun 30, 2026 |
Identity
- SEC CIK
- 1711279